The horizontal layer is built.
What's missing is the vertical depth.

Datasite has spent the last twelve months building one of the clearest deal‑intelligence platform plays in the market. Grata, Sourcescrub, and Blueflame closed the breadth and AI‑workflow gaps. The remaining gap — vertical depth in the single largest M&A vertical by deal value — cannot be built in time to matter. Galen Growth has spent eleven years building exactly that.

The strategic role. HealthTech Alpha is the AI-workflow-assisted catalyst that converts Datasite from an M&A workflow platform into a fully end-to-end investment and commercial process enabler in healthcare — extending Datasite's reach all the way upstream to the deal-sourcing origin point for private healthcare deals, and downstream into pharma, payer, and institutional-investor decision workflows.

The value anchor — cost and execution risk to replicate. Replicating Galen Growth today is not a pure software build — it is a multi‑year effort (5–7 years) requiring substantial capital and coordinated execution across proprietary data, AI infrastructure, expert validation, and global commercial traction. On a fully burdened basis, recreating a comparable asset would likely require on the order of $40M to $90M of cumulative investment, with no assurance of achieving equivalent data depth, credibility, or market position within that timeframe. The central risk is not just cost, but execution — specifically whether the data asset, ontology, and market trust can be successfully assembled at all in today's environment. The Galen Growth principals are explicitly flexible on transaction structure and terms; the conversation is about alignment with Datasite's long‑term value‑creation thesis.

The intelligence axis Datasite has built

Sourcing

Grata · Sourcescrub

Intelligence

16M companies · 220k sources

Vertical depth

Galen Growth — Healthcare

AI workflow

Blueflame · MCP Server

Execution

Diligence · Acquire · Prepare

Galen Growth slots in as the vertical layer underneath the existing horizontal intelligence — and closes the unfilled healthcare vertical‑leadership gap.

The strategic numbers

CapVest commitment

$500M

Announced with Grata, June 2025. Explicitly organic and inorganic. Blueflame (Jul 2025) and Sourcescrub (Aug 2025) have consumed part — meaningful capacity remains.

Galen Growth coverage

17,000+

Digital health companies tracked across 100+ countries. 300M+ structured & unstructured data points. Proprietary medical taxonomy, evidence‑graded.

Pharma M&A rank

Largest M&A vertical by deal value globally. Healthcare & Life Sciences is one of three named Datasite Forecaster content franchises.

Replication effort

$40–90M

Cumulative, fully‑burdened investment over 5–7 years to recreate the asset — with no guarantee of equivalent depth, credibility, or market position. Execution risk, not just cost.

What Grata reaches — and what it can't

What the Grata + Sourcescrub layer reaches

~16M companies via 220k+ information sources
Website‑crawl + ML taxonomy (generic by design)
Strong middle‑market US coverage breadth
PE / search‑fund / corporate‑development sales channel
AI‑native, integrates with Blueflame & MCP Server

What it can't produce — and what Galen Growth provides

Clinical taxonomy & medical ontology — not inferable from crawls
Evidence grading — peer‑reviewed clinical evidence vs. marketing claims
Therapeutic category, regulatory pathway, reimbursement context
Eleven years of human curation across 17,000+ digital health ventures
Pharma / medical device / payer / health‑system customer base
Named healthcare‑vertical leadership inside the intelligence stack

Build alternative is execution risk, not just cost — a 5–7 year, $40M–$90M fully‑burdened effort with no guarantee of equivalent depth, credibility, or market position. Acquisition timeline: 90 days.

The integration template is already running

Grata operates as a strategic business unit inside Datasite. Co‑founders Andrew Bocskocsky (EVP, Private Markets Intelligence) and Nevin Raj (now also COO, Data & AI for Datasite) were retained to lead it. Sourcescrub was folded into Grata, not into the Datasite mothership — preserving the data‑layer brand while Datasite remains the workflow brand.

Galen Growth slots into the same template. HealthTech Alpha is preserved as the data brand. Leadership is retained. No Datasite product‑team bandwidth is reallocated. Bocskocsky and Raj's existing playbook applies almost directly. Galen Growth's data plugs into Datasite Forecaster's healthcare content engine. The Grata sales channel — PE, search funds, corporate development — gains a vertical product to upsell. Galen Growth's principals fill the unfilled healthcare vertical‑leadership role.

Grata gave Datasite horizontal breadth. Galen Growth gives Datasite vertical depth in the one M&A vertical where breadth alone is not credible to the buyer — and where Datasite already hosts the largest customer relationships, but has no named vertical leader. — Kane & Company strategic rationale

The competitive position

SS&C Intralinks	AI feature investments but no Grata‑equivalent intelligence acquisition. The vertical‑depth move widens the workflow‑intelligence moat against them.
Ansarada · Firmex	No intelligence layer at all. Not a competitive threat in this play.
PitchBook	Horizontal and weak on digital health specifically and on evidence‑graded data generally. Acquiring Galen Growth is a flank attack in the highest‑value vertical without requiring a horizontal contest.
CB Insights · Crunchbase	Narrative‑driven and shallower. No vertical healthcare depth at the Galen Growth level.

Galen Growth — the company

Founded	2015, Singapore. Eleven years of operating history.
Platform	HealthTech Alpha — AI‑driven SaaS. 17,000+ digital health companies. 100+ countries. 300M+ structured & unstructured data points.
Differentiators	Proprietary medical taxonomy. Evidence grading. Eleven years of human curation.
Customer base	Top‑tier pharma, medical device, payer, insurer, health system, institutional investor, strategy consultancy.
Distribution proof	November 2024 commercial partnership with Evaluate (Norstella) — bringing HealthTech Alpha data into Evaluate's customer base. The data layer is platform‑portable.

A 30‑minute conversation

The detailed Internal Rationale Memo — written as source material for Datasite leadership to use internally — is ready to share on request. The first conversation can start with Nevin Raj and Andrew Bocskocsky on platform fit and Pallavi Pal on Grata product fit.

Reply to Michael Kane →

The horizontal layer is built.What's missing is the vertical depth.